Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 4/20 | 0.66 |
| ▸ | MMP2 | P08253 | 4/20 | 0.66 |
| ▸ | MMP9 | P14780 | 4/20 | 0.66 |
| ▸ | MAOB | P27338 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.53 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21646072 | 1.00 | MMP1 (0.66) | MMP1MMP2MMP9MAOBMEN1 | |
| SCHEMBL7822560 | 0.83 | LPAR1 (0.77) | MMP1MMP2MMP9MAOBMEN1 | |
| SCHEMBL7822564 | 0.83 | LPAR1 (0.77) | MMP1MMP2MMP9MAOBMEN1 | |
| SCHEMBL11756411 | 0.83 | MMP1 (0.66) | MMP1MMP2MMP9MAOBMEN1 | |
| SCHEMBL12835303 | 0.82 | MMP1 (0.64) | MMP1MMP2MMP9MAOBMEN1 | |
| SCHEMBL705746 | 0.80 | MMP1 (1.00) | MMP1MMP2MMP9MAOBMEN1 | |
| SCHEMBL705745 | 0.80 | MMP1 (1.00) | MMP1MMP2MMP9MAOBMEN1 | |
| SCHEMBL1380349 | 0.79 | TGM2 (0.65) | MMP1MMP2MMP9MAOBMEN1 | |
| SCHEMBL31162287 | 0.79 | TGM2 (0.65) | MMP1MMP2MMP9MAOBMEN1 | |
| SCHEMBL13375061 | 0.79 | MEN1 (0.61) | MMP1MMP2MMP9MAOBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162855-B2 | Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2024-12-10 | — | — | US | disclosed |
| EP-3830079-A1 | TETRAHYDROQUINOLINO DERIVATIVES FOR THE TREATMENT OF METASTATIC AND CHEMORESISTANT CANCERS | The Trustees of Princeton University (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20210155602-A1 | TETRAHYDROQUINOLINO DERIVATIVES FOR THE TREATMENT OF METASTATIC AND CHEMORESISTANT CANCERS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2021-05-27 | — | — | US | disclosed |
| WO-2020028461-A1 | TETRAHYDROQUINOLINO DERIVATIVES FOR THE TREATMENT OF METASTATIC AND CHEMORESISTANT CANCERS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155602-A1 | TETRAHYDROQUINOLINO DERIVATIVES FOR THE TREATMENT OF METASTATIC AND CHEMORESISTANT CANCERS | ALDH3A1, ALDH1A3, ALDH2 | MMP1 3297/4885MMP2 736/4885MMP9 2127/4885 |
| US-12162855-B2 | Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers | ALDH3A1, ALDH2, ALDH1A1 | MMP1 2019/4885MMP2 469/4885MMP9 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.